Your session is about to expire
← Back to Search
Checkpoint Inhibitor
Nivolumab + Ipilimumab for Lung Cancer (ATLAS Trial)
Phase 2
Recruiting
Led By Adrian Sacher, M.D.
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
No prior radiation, surgery or chemotherapy is allowed for the current diagnosis of non-small cell lung cancer
Recurrent or newly diagnosed metastatic non-small cell lung cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
ATLAS Trial Summary
This trial will test the effectiveness of two drugs, nivolumab and ipilimumab, for treating non-small cell lung cancer that has metastasized.
Who is the study for?
Adults with metastatic non-small cell lung cancer, weighing at least 35 kg and expected to live more than 12 weeks. They must not have had prior treatments for this diagnosis or certain other cancers in the last two years, no major organ transplants, active infections like HIV or hepatitis, and no recent heart issues. Participants need functioning organs/marrow and cannot be on immunosuppressants.Check my eligibility
What is being tested?
The trial is testing the effectiveness of nivolumab and ipilimumab drugs on metastatic non-small cell lung cancer. It also examines how a cfDNA blood test can help track tumor changes during treatment. Patients will not have received previous surgery, radiation, or chemotherapy for their current cancer diagnosis.See study design
What are the potential side effects?
Nivolumab and Ipilimumab may cause immune system-related side effects such as inflammation in various body parts (like lungs or intestines), skin rashes, hormone gland problems (like thyroid), liver inflammation, infusion reactions (during drug administration), fatigue, weakness.
ATLAS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have not had any treatment for my current lung cancer diagnosis.
Select...
My lung cancer has returned or spread to other parts.
Select...
My tumor's PDL1 level is below 50%.
Select...
My cancer does not have mutations like EGFR, ALK, or ROS1.
Select...
I weigh at least 35 kilograms.
Select...
I am fully active or can carry out light work.
ATLAS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of participants whose disease does not worsen (progression-free survival rate) at 6 months
Secondary outcome measures
Average percentage of tumor cfDNA detected in the blood (tumor cfDNA clearance rate) at 12 weeks
Cell-Free DNA
Average time from the date of study enrolment until death (overall survival)
+1 moreATLAS Trial Design
1Treatment groups
Experimental Treatment
Group I: Non-Small cell Lung CancerExperimental Treatment4 Interventions
Nivolumab, intravenously (given by vein), once every 3 weeks Ipilimumab, intravenously (given by vein), once every 6 weeks
Participants will have blood samples taken for cell free deoxyribonucleic acid (cfDNA) testing.
If there is an increasing or stable tumor cfDNA, platinum-doublet chemotherapy will be given.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Platinum-based Chemotherapy
2017
Completed Early Phase 1
~570
Nivolumab
2014
Completed Phase 3
~4750
Ipilimumab
2014
Completed Phase 3
~2620
Find a Location
Who is running the clinical trial?
Bristol-Myers SquibbIndustry Sponsor
2,640 Previous Clinical Trials
4,129,414 Total Patients Enrolled
University Health Network, TorontoLead Sponsor
1,474 Previous Clinical Trials
484,992 Total Patients Enrolled
Adrian Sacher, M.D.Principal InvestigatorPrincess Margaret Cancer Centre
1 Previous Clinical Trials
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not incarcerated and can consent and follow study procedures.I haven't taken immunosuppressive drugs in the last 14 days, with some exceptions.I have not had any treatment for my current lung cancer diagnosis.I've had to stop IV drug treatments more than once due to bad reactions.I haven't had cancer treatment or palliative radiotherapy in the last 3 weeks.I have previously received immunotherapy.I have had an autoimmune disorder in the last 3 years.All my side effects from previous treatments, except for hair loss, have gone back to normal.I do not have any severe illnesses or social situations that would prevent me from following the study's requirements.My lung cancer has returned or spread to other parts.My lung cancer can be of any type.My surgery did not remove all of my cancer.My tumor's PDL1 level is below 50%.I haven't had a heart attack, stroke, or severe heart failure in the last 3 months.My cancer does not have mutations like EGFR, ALK, or ROS1.I have a history of immune system issues, organ transplant, or active tuberculosis.I have not had any other cancer besides non-invasive types in the last 2 years.You have HIV, chronic or active hepatitis B or C, or active hepatitis A.I haven't had a live vaccine or major surgery in the last 30 days.You are expected to live for at least 12 more weeks.I weigh at least 35 kilograms.I am fully active or can carry out light work.I am not pregnant, breastfeeding, nor plan to become pregnant during the study.My organs and bone marrow are working well.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Non-Small cell Lung Cancer
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any historical records of Ipilimumab being tested in a research setting?
"Currently, 918 clinical trials are active, with 144 being in the third phase. Most of these studies take place in Xiamen, Fujian; however there is a large presence of studies for Ipilimumab distributed across 59,988 different locations worldwide."
Answered by AI
Are there any vacancies currently available for participation in this trial?
"Affirmative. Per the information on clinicaltrials.gov, this medical trial has been looking for patients since January 24th 2022 and is actively recruiting as of May 9th 2021. The goal is to sign up 50 individuals at 1 site."
Answered by AI
To what extent could Ipilimumab be detrimental to patients?
"Ipilimumab has been evaluated in a Phase 2 clinical trial, meaning there is evidence of safety but not necessarily efficacy. Thus our team at Power assessed the drug's safety on a scale from 1 to 3 and gave it a score of 2."
Answered by AI
What conditions are usually managed with Ipilimumab?
"Ipilimumab is a commonly employed anti-angiogenic treatment, and has also been found to be an effective therapeutic option for individuals with malignant neoplasms, unresectable melanoma, and squamous cell carcinoma."
Answered by AI
Approximately how many subjects are participating in this trial?
"Correct. Clinicaltrials.gov corroborates that this research project, originally posted on January 24th 2022 is currently recruiting participants. The trial requires 50 subjects from 1 site to be enrolled in the study."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger